

Comparison of Ventilator-Free Days at 14 and 28 days as a Clinical Trial Outcome in Low- and Middle-Income Countries

Arun K Baranwal¹, Praveen Kumar-M², Pramod K Gupta³

ABSTRACT

Objectives: Reporting ventilator-free days (VFDs) with time frame of 28 days is a popular composite outcome measure (COM) in trials. However, early deaths and shorter pediatric intensive care unit (PICU) stay predominate in low- and middle-income countries (LMICs). A shorter time frame may reduce sample size required. We planned to compute sample size requirements for different effect sizes from datasets of previously conducted prospective studies for 28-day and 14-day time frames (VFD₂₈ vs VFD₁₄) to examine the hypothesis.

Materials and methods: The VFD₂₈ and VFD₁₄ were defined. Datasets of five prospective studies from PICU of our hospital were analyzed to estimate sample sizes for target reductions of 1–9 days in VFDs and other COMs for the two time frames. Reconfirmation of results was done with datasets of two other studies from PICUs of two geographical extremes of the country.

Results: Time-to-event occurred within 14 days in majority of patients. Sample size required for VFD₁₄ is about one-fifth to one-sixth of what is required for VFD₂₈ for target reductions of 1–9 days for all the enrolled studies. The same was true for other COMs as well. The hypothesis was supported by datasets of two other studies used for reconfirmation.

Conclusion: Choice of time frame for assessing VFDs and other COMs in clinical trials should be guided by the clinical context. A shorter time frame may be rewarding in terms of smaller sample size in the prevalent clinical setting of LMICs. Further confirmation with more datasets and prospective studies is desirable.

Keywords: Children, Clinical trials, Composite outcome measures, Intensive care, Low- and middle-income countries, Ventilator-free days.

Indian Journal of Critical Care Medicine (2020): 10.5005/jp-journals-10071-23568

INTRODUCTION

Mortality in critically ill patients is multifactorial, and reduction with anyone intervention is unlikely in the current era.¹ Mortality difference as endpoint would need large sample, which may not only be expensive and difficult to manage but it is also unethical to enroll large number of patients if smaller sample can give similar conclusion.^{1–3} Thus, clinical researchers resorted to composite outcome measures (COMs) like ventilator-free days (VFDs), which summarizes both ventilator days and mortality. Improvement in VFDs and other similar COMs, whose parallelism with mortality has been proven statistically, may not only increase cost-effectiveness of an intervention but also improve the survival.^{1,2,4} Ventilator-free day is used as primary endpoint in clinical trials^{3,5,6} despite its limitations.^{4,5} Other popular COMs are vasoactive-inotrope-free days,^{6,7} organ failure-free days (OFFDs),⁷ renal replacement-free days,⁶ ICU-free days,^{8–10} and hospital-free days.^{9,11,12}

Deaths among critically ill patients have two peaks—“early” ones (i.e., during 14 days) are due to inadequate resuscitation, while “late” ones (i.e., beyond 3rd week) are due to persistence of existing organ dysfunctions and/or appearance of new ones.¹³ Significant reduction in “early” deaths in high-income countries (HICs) due to effective implementation of resuscitative care bundles^{2,13} has shifted the focus to “late” deaths, which are affected by high prevalence of comorbidities.^{2,13–17} Thus, clinical efficacy of interventions is likely to be apparent only over a longer observation period necessitating VFD to be reported in 28 days.^{2,4,13,18} However, in low- and middle-income countries (LMICs), critical illnesses are mostly due to acute communicable diseases causing septic shock,^{14,19–24} acute respiratory distress syndrome (ARDS),^{19,25–28} acute meningoencephalitis,²⁹ and multiorgan failure in apparently healthy immunocompetent patients without

¹Department of Pediatrics, Advanced Pediatric Centre, Postgraduate Institute of Medical Education and Research, Chandigarh, India

²Department of Pharmacology, Postgraduate Institute of Medical Education and Research, Chandigarh, India

³Department of Biostatistics, Postgraduate Institute of Medical Education and Research, Chandigarh, India

Corresponding Author: Arun K Baranwal, Department of Pediatrics, Advanced Pediatric Centre, Postgraduate Institute of Medical Education and Research, Chandigarh, India, Phone: +91 7766908325, e-mail: baranwal1970@gmail.com

How to cite this article: Baranwal AK, Kumar-M P, Gupta PK. Comparison of Ventilator-Free Days at 14 and 28 days as a Clinical Trial Outcome in Low- and Middle-Income Countries. *Indian J Crit Care Med* 2020;24(10):960–966.

Source of support: Nil

Conflict of interest: None

significant comorbidities. Pediatric intensive care units (PICUs) of various LMICs (e.g., Pakistan,^{22,23} India,^{19,20,24,26,29} Brazil,^{25,30} Singapore²⁸) report need of shorter (7–14 days) ventilation and/or PICU stay in majority of patients. “Early deaths” in patients from LMICs are attributable to suboptimal acute care facilities, late referral, and poor implementation of time-tested and clinically proven resuscitative bundles.³¹

There is a felt need of appropriate time frames for calculation of VFDs and other COMs according to the time-to-outcome events,^{4,32} which is likely to be different in different clinical settings as discussed above. We proposed concept of a shorter time frame (of 14 days) for VFDs and OFFDs in a study in the year 2008^{19,33} and reported acute care area-free days (ACAFDs) with time frame of 14 days for

recently.²⁰ Review of datasets of our previously published studies revealed a considerably lower standard deviation (SD) of the means of VFDs and ACAFDs, respectively, for time frame of 14 days (VFD₁₄) compared to that of 28 days (VFD₂₈).^{19,20} As sample size calculation considers SD of the endpoint, we hypothesized that setting a shorter time frame (14 day instead of 28 day) as a COM is likely to reduce the sample size. This *post hoc* analysis was planned to test this hypothesis based on inputs from previously conducted studies.

MATERIALS AND METHODS

Patients

The study was planned as a *post hoc* analysis. We studied patients enrolled in seven studies,^{19,20,27,34-37} out of which four are published.^{19,20,27,36} Six of these studies were conducted at Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, while one was conducted at Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry.³⁷ Deidentified datasets were obtained by contacting

the corresponding authors of the respective studies. We planned to use information from five studies of PGIMER, Chandigarh for evaluation of hypothesis. We then checked if the observed findings were true from datasets of two studies, which we called as reconfirmation cohort: one study from PGIMER, Chandigarh³⁶ and one from JIPMER, Puducherry.³⁷ Data for VFDs were available in three studies only, while data for other COMs were available in other studies.

We computed sample size required for interventional studies based on VFD and other COMs with reference to 28 days and 14 days with varying effect size (from 1 free day to 9 free days), and decided to compare the fold change in requirement of sample size. Definition of VFD and other COMs evaluated are detailed in Table 1. The first step was to compute these COMs for the included studies from the available datasets. All data required to calculate the considered COMs were not reported in the included studies. Data for calculating VFDs were present in three studies,^{19,27,34} for PICUFDs were present in three studies,^{19,34,35} for OFFDs and ACAFDs was present in one study each.^{19,20} After computation of

Table 1: Definition of various composite outcome measures in reference to day 28 and day 14 time frames

Outcome name	Outcome definition
VFD-28 ¹ (ventilator-free days in 28 days)	VFD ₂₈ = 0: If patient dies before 28 days of ventilation VFD ₂₈ = 0: If patient requires ventilation for >28 days VFD ₂₈ = (28 - x): If patient survives and got weaned from ventilation within 28 days, where "x" is the number of days on ventilation
VFD-14 ¹⁹ (ventilator-free days in 14 days)	VFD ₁₄ = 0: If patient dies before 14 days of ventilation VFD ₁₄ = 0: If patient requires ventilation for >14 days VFD ₁₄ = (14 - x): If patient survives and got weaned from ventilation within 14 days, where "x" is the number of days on ventilation
PICUFD-28 (pediatric intensive care unit-free days in 28 days)	PICUFD ₂₈ = 0: If patient dies within 28 days of PICU stay PICUFD ₂₈ = 0: If patient requires PICU stay for >28 days PICUFD ₂₈ = (28 - x): If patient survives and got discharged from PICU within 28 days, where "x" is the number of PICU stay in days
PICUFD-14 (pediatric intensive care unit-free days in 14 days)	PICUFD ₁₄ = 0: If patient dies within 14 days of PICU stay PICUFD ₁₄ = 0: If patient requires PICU stay for >14 days PICUFD ₁₄ = (14-x): If patient survives and got discharged from PICU within 14 days, where "x" is the number of PICU stay in days
OFFD-28 (organ failure-free days in 28 days)	OFFD ₂₈ = 0: If patient dies within 28 days of developing an organ failure OFFD ₂₈ = 0: If patient has an organ failure for >28 days OFFD ₂₈ = (28-x): If patient survives and becomes free from every organ failure within 28 days, where "x" is the number of days of organ failure
OFFD-14 (organ failure-free days in 14 days)	OFFD ₁₄ = 0: If patient dies within 28 days of developing an organ failure OFFD ₁₄ = 0: If patient has an organ failure for >28 days. OFFD ₁₄ = (14 - x): If patient survives and becomes free from every organ failure within 14 days, where "x" is the number of days of organ failure
ACAFD-28 (acute care area free days in 28 days)	ACAFD ₂₈ = 0: If patient dies within 28 days of ACA stay ACAFD ₂₈ = 0: If patient requires ACA stay for >28 days. ACAFD ₂₈ = (28 - x): If patient survives and got discharged from ACA within 28 days, where "x" is the number of ACA stay in days
ACAFD-14 (acute care area free days in 14 days)	ACAFD ₁₄ = 0: If patient dies within 14 days of ACA stay ACAFD ₁₄ = 0: If patient requires ACA stay for >14 days ACAFD ₁₄ = (14 - x): If patient survives and got discharged from ACA within 14 days, where "x" is the number of ACA stay in days

COMs, the mean and SD were calculated. In case of observational study,²⁰ SD was based on the entire study population. There were no difference in the COMs between intervention arms of the interventional studies.^{19,27,34,35} Thus, we did not take intervention into consideration and calculated the mean and SD of the entire study population considering them as unity. After computation of mean and SD, the next step was the calculation of sample size for each COM. Approval from ethics committees of respective hospitals had already been obtained for each individual study from which the data were obtained. Hence, a separate ethical approval for the current *post hoc* analysis was deemed not to be required. The analysis was approved by the Departmental Review Board of Department of Pediatrics at PGIMER, Chandigarh.

To justify that the time frame of 14 days is relevant in our clinical setting, we planned to compare if the outcome event (i.e., mortality and freedom from the considered morbidity, e.g., ventilation duration in case of VFDs) occurred in the majority within 14 days or afterward. Hence, we plotted Kaplan Meier curves to evaluate time-to-outcome event (i.e., time-to-death and time-to-extubation in case of VFDs) from datasets of the included studies. The 30-day median survival time (with 95% confidence interval) was computed.

Computation of the Required Sample Size

We assumed that COMs follow normal distribution. For simplicity, we assessed the sample size required for comparison between two independent groups based on COM. We varied the effect size between 1 free day and 9 free days for the COMs. The sample size computation formula for comparing two independent means based on equality assumption, i.e., unpaired *t*-test, is:

$$n = \left[2(Z_{\alpha/2} + Z_{\beta})^2 * SD^2 \right] / d^2$$

(where *Z*, normal distribution; α , type I error; β , type II error; *d*, mean difference ($\mu_1 - \mu_2$) (where μ_1 and μ_2 , means of the two groups); SD, pooled standard deviation).

We kept two-sided significance along with type I error at 0.05 and type II error at 0.2 (power 0.8) for all the calculations. The sample size computed was for single group. From this information, sample size required for VFDs and other COMs with time frames of 28 days and 14 days were compared. Statistical analysis was done using R version 3.5.1³⁸ and its additional packages like *pwr*,³⁹ *ggplot2*,⁴⁰ and *pROC*.⁴¹

RESULTS

Characteristics of the studies included for concept evaluation as well as the studies used for reconfirmation and relevant data summary therefrom are shown in Table 2.

Time-to-Outcome Event in the Included Studies

Kaplan Meier curves for time-to-outcome event (death or extubation) for three representative studies (Choudhary,³⁴ Jain,³⁷ and Yadav et al.³⁶) are shown in Figure 1. The 30-day median time to event for death was 11 days (95% CI, 7–14) and 9 days (95% CI, 7–13) in the studies by Jain³⁷ and Yadav et al.,³⁶ respectively. The median survival time for the Choudhary's study³⁴ could not be calculated as mortality was less than 50%. The 30-day median time to event for extubation was 9 days (95% CI, 7–12), 6 days (95% CI, 5–8), and 7.5 days (95% CI, 6–10) in the studies by Choudhary,³⁴ Jain,³⁷ and Yadav et al.,³⁶ respectively.

Estimation of Sample Size with VFD14 and VFD28

Utilizing datasets from studies of Baranwal et al.,¹⁹ Lalgudi Ganesan et al.,²⁷ and Choudhary,³⁴ the comparative analysis of computed requirement of sample size to prove significance for VFD₁₄ and VFD₂₈ is shown in Figure 2. The curves for VFD₁₄ and VFD₂₈ converge with increase in effect size; however, the ratio between them remained approximately same throughout. The estimated sample sizes for target reductions of 1 day, 5 days, and 9 days are shown in Table 3. Sample sizes required for VFD₂₈ are 5.99, 5.91, and 6.65 times of that are required for VFD₁₄ for target reduction of 1 day based on the dataset from Baranwal et al.,¹⁹ Lalgudi Ganesan et al.,²⁷ and Choudhary,³⁴ respectively. Similarly, 5.33, 5.36, 6.11 and 5.0, 4.8, 4.5 times bigger samples are required for VFD₂₈ compared to that of VFD₁₄ for target reductions of 5 and 9 days, respectively, in these three studies. On an average, 6.19 ± 0.41 , 5.60 ± 0.44 , and 4.77 ± 0.25 times larger samples are required for VFD₂₈ compared to VFD₁₄ for target reduction of 1, 5, and 9 days respectively. Similar trends were seen for other COMs (Table 3). Studies used for reconfirmation of the hypothesis also revealed similar results (Tables 2 and 3).

DISCUSSION

In the current *post hoc* analysis of datasets from previously conducted studies at our tertiary care teaching hospital, we demonstrated that death and extubation predominantly occurred within 14 days. By reducing time frame of VFDs to 14 days, required sample size got significantly reduced compared to that of 28 days. The desired difference of VFD was varied between 1 and 9 days for sample size calculation as mean duration of ventilation among survivors was 8–11 days.^{19,27,34} Approximately five and half times less sample is required for the time frame of 14 days compared to that of 28 days. It provided a proof of concept to our hypothesis. Datasets of another study from our hospital and a study from a hospital situated in southern part of India^{36,37} further supported it.



The VFDs and other COMs are widely being used to reduce sample size while capturing clinically meaningful outcomes.^{1,2,4,5} Though time frames of 28 days or longer are popular in the studies from HICs, questions are being raised regarding clinical utility of longer observation period if majority of patients experience the outcome event in a shorter time frame.^{5,32} Most of children in PICUs of the LMICs are suffering from easily treatable communicable diseases and do not have significant comorbidities compared to those in HICs. Consequently, majority require shorter ventilation and PICU stay as demonstrated in the current analysis. Bodet-Contentin et al.⁴ suggest “the time horizon should be established in light of the medical context i.e., when one can reasonably expect that most patients are extubated or dead.” Yehya et al. concluded with similar sentiments in their reappraisal of VFDs.³² A shorter time frame (i.e., 14 days) is likely to help design fully powered trials with smaller samples for shorter observation period, which is likely to impact feasibility and cost of conducting a trial. It may improve generation of quality scientific data from LMICs to arrive at meaningful conclusions with potentially useful interventions.

Earlier studies demonstrated that statistical properties of VFDs depend on choice of time frame (14, 28, 60, or 90 days) and method of hypothesis testing (nonparametric vs parametric test).^{1,4} The parametric test (e.g., Student's *t*-test) is likely to reduce weightage for survivals for 14-day time frame compared to 28-day time frame because survivals would have less VFDs in case of the former.¹ Thus, nonparametric test (e.g., Wilcoxon rank-sum test) is advised for the


Table 2: Characteristics of the included studies

Studies	Study design	Nature of enrolled patients	Intervention if any	Sample size	Mortality, n (%)	VFD ₁₄ (mean ± SD)	VFD ₂₈ (mean ± SD)	SD taken for computing sample size for VFD ₁₄	SD taken for computing sample size for VFD ₂₈
Baranwal et al. ¹⁹	Interventional study	ARDS	Oral ambroxol vs placebo	66	17 (26)	4.70 ± 4.07	14.36 ± 9.98	4.07	9.98
Lalgudi Ganesan et al. ²⁷	Interventional study	ARDS	APRV vs standard ventilation	52	21 (40)	4.12 ± 4.47	11.96 ± 10.89	4.47	10.89
Choudhary ³⁴	Interventional study	ARDS	Lower vs higher hemoglobin threshold for transfusion	40	9 (23)	3.65 ± 3.58	13.23 ± 9.25	3.58	9.25
Baranwal et al. ¹⁹	Interventional study	ARDS	Oral ambroxol vs placebo	66	17 (26)	7.92 ± 5.59	17.76 ± 11.45	5.59	11.45
Baranwal et al. ¹⁹	Interventional study	ARDS	Oral ambroxol vs placebo	66	17 (26)	2.23 ± 3.01	11.32 ± 8.46	3.01	8.46
Gupta ³⁵	Interventional study	Septic shock	Normal saline vs plasmalyte	44	10 (23)	4.61 ± 4.36	14.64 ± 9.64	4.36	9.64
Choudhary ³⁴	Interventional study	ARDS	Lower vs higher hemoglobin threshold for transfusion	40	9 (23)	2.40 ± 3.22	10.70 ± 9.04	3.22	9.04
Ghosh et al. ²⁰	Observational study	Septic shock	None	42	16 (38)	3.40 ± 4.07	11.81 ± 10.07	4.07	10.07
Jain ³⁷	Interventional study	Septic shock	EGDT vs standard care	120	61 (51)	3.36 ± 4.22	9.72 ± 10.72	4.22	10.72
Yadav et al. ³⁶	Observational study	ARDS	None	98	54 (55)	2.49 ± 3.78	8.01 ± 10.10	3.78	10.10
Jain ³⁷	Interventional study	Septic shock	EGDT vs standard care	120	61 (51)	2.36 ± 3.42	8.45 ± 9.78	3.42	9.78

RCT, randomized controlled trial; VFD, ventilation-free days; OFFD, organ failure-free days; PICUFD, pediatric intensive care unit-free days; ACAFD, acute care area-free days; ROC AUC, receiver operating characteristics area under curve; EGDT, early goal-directed therapy; APRV, airway pressure release ventilation



Figs 1A and B: Kaplan Meier curves to show the time to event for deaths (A) and extubations (B) in three recent studies from India (Choudhary,³⁴ Jain,³⁷ and Yadav et al.³⁶ Horizontal lines represent the median time to event. In the study by Choudhary,³⁴ the median time to death could not be computed (A), as the mortality was <50% during the observation period of 30 days



Figs 2A to C: Comparison of the estimated sample sizes in one arm for various target increments in VFDs for time frames of 14 days (VFD₁₄) vs 28 days (VFD₂₈) based on the real dataset from: (A) Baranwal et al.;¹⁹ (B) Lalgudi Ganesan et al.;²⁷ (C) Choudhary³⁴

Table 3: Comparison of calculated sample sizes required in one arm for three target increments (1, 5, and 7 days) in various composite outcome measures for time frames of 14 and 28 days

		<i>Comparison of sample sizes required in one arm for different target increments in the respective composite outcome measures with respect to the two time frames</i>		
<i>Studies</i>		<i>1 day's increment</i>	<i>5 days' increment</i>	<i>9 days' increment</i>
Studies used for evaluation of concept				
1.	Baranwal et al. ¹⁹ VFD ₁₄ :VFD ₂₈	261:1565	12:64	4:20
2.	Lalgudi Ganesan et al. ²⁷ VFD ₁₄ :VFD ₂₈	315:1863	14:75	5:24
3.	Choudhary ³⁴ VFD ₁₄ :VFD ₂₈	202:1344	9:55	4:18
4.	Baranwal et al. ¹⁹ OFFD ₁₄ :OFFD ₂₈	492:2059	21:83	7:26
5.	Baranwal et al. ¹⁹ PICUFD ₁₄ :PICUFD ₂₈	143:1125	7:46	3:15
6.	Gupta ³⁵ PICUFD ₁₄ :PICUFD ₂₈	299:1460	13:59	5:19
7.	Choudhary ³⁴ PICUFD ₁₄ :PICUFD ₂₈	164:1284	8:52	3:17
8.	Ghosh et al. ²⁰ ACAFFD ₁₄ :ACAFFD ₂₈	261:1593	11:65	4:21
Studies used for reconfirmation of concept				
9.	Yadav et al. ³⁶ VFD ₁₄ :VFD ₂₈	225:1602	10:65	4:21
10.	Jain ³⁷ VFD ₁₄ :VFD ₂₈	281:1805	12:73	5:23
11.	Jain ³⁶ PICUFD ₁₄ :PICUFD ₂₈	185:1502	8:61	4:20

VFD, ventilation-free days; OFFD, organ failure-free days; PICUFD, pediatric intensive care unit-free days; ACAFFD, acute care area-free days

extremely skewed VFD distribution as it will be independent of the length of time frame.^{1,4} However, reducing time frame from 28 to 14 days is likely to reduce skewness of VFDs and increase applicability of the parametric test.³² Further, the *t*-test is considered adequate

for sufficiently large sample size (>30 patients).⁴ All the included studies for the current analysis have reasonable sample size. Though Gray's test and Fine and Gray regression test are suggested to be preferred over Wilcoxon rank-sum test or Student's *t*-test for

assessment of competing events (mortality and ventilator days) by comparing the cumulative incidence functions,^{4,32} the former ones are not popular even in recently conducted clinical trials^{42–44} and *post hoc* analysis.⁴⁵ Moreover, Student's *t*-test performed well while evaluating power of study for different outcomes compared to Grey's test and Fine and Gray regression test.³²

Median time-to-outcome event for death and extubation in our PICUs is demonstrably less than 14 days; however, a comparative analysis of datasets from HICs and other LMICs would have improved interpretation. Considering small and single-center studies arbitrarily without a predefined protocol is a limitation. Potential bias toward a specific clinical setting cannot be ruled out as all the datasets included are from one country, and all except one are from a single hospital. However, the statistical approach and calculated sample sizes therefrom are strong enough to provide a scientifically meaningful proof of concept. Validation of the concept from more datasets in a more scientific manner is likely to improve external validity.

CONCLUSION

The *post hoc* analysis provided a proof of concept that choice of the time frame for assessing VFDs and other COMs should be guided by the clinical context and the time-to-outcome event. A shorter time frame of 14 days is likely to require much smaller sample size compared to the time frame of 28 days in LMICs especially among pediatric patients. However, it needs to be validated with more datasets and prospective studies.

ACKNOWLEDGMENTS

We would like to thank Prof Jayashree Muralidharan, Dr Arun Bansal, Dr Shalu Gupta, Dr Abhijit Choudhary, and Dr Puneet Jain to provide real datasets of their studies.

ROLE OF CONTRIBUTORS

Arun K Baranwal conceived the idea of usefulness of shorter time horizon for composite endpoints from the dataset of his studies, conceptualized the same, prepared the final draft of the manuscript, and will act as guarantor. Arun K Baranwal and Praveen Kumar-M did literature search and statistical analysis. Praveen Kumar-M prepared the first draft of the manuscript. Pramod K Gupta critically reviewed the statistical analysis and manuscript and suggested valuable modifications.

REFERENCES

1. Schoenfeld DA, Bernard GR. ARDS network. Statistical evaluation of ventilator-free days as an efficacy measure in clinical trials of treatments for acute respiratory distress syndrome. *Crit Care Med* 2002;30(8):1772–1777. DOI: 10.1097/00003246-200208000-00016.
2. Weiss SL, Fitzgerald JC, Pappachan J, Wheeler D, Jaramillo-Bustamante JC, Salloo A, et al. Sepsis prevalence, outcomes, and therapies (SPROUT) study investigators and pediatric acute lung injury and sepsis investigators (PALISI) network. global epidemiology of pediatric severe sepsis: the sepsis prevalence, outcomes, and therapies study. *Am J Respir Crit Care Med* 2015;191(10):1147–1157. DOI: 10.1164/rccm.201412-2323OC.
3. Montori VM, Permyer-Miralda G, Ferreira-González I, Busse JW, Pacheco-Huergo V, Bryant D, et al. Validity of composite endpoints in clinical trials. *BMJ* 2005;330(7491):594–596. DOI: 10.1136/bmj.330.7491.594.

4. Bodet-Contentin L, Frasca D, Tavernier E, Feuillet F, Foucher Y, Giraudeau B. Ventilator-free day outcomes can be misleading. *Crit Care Med* 2018;46(3):425–429. DOI: 10.1097/CCM.0000000000002890.
5. Contentin L, Ehrmann S, Giraudeau B. Heterogeneity in the definition of mechanical ventilation duration and ventilator-free days. *Am J Respir Crit Care Med* 2014;189(8):998–1002. DOI: 10.1164/rccm.201308-1499LE.
6. Hernández G, Ospina-Tascón GA, Damiani LP, Estenssoro E, Dubin A, Hurtado J, et al. For the ANDROMEDA-SHOCK investigators and the latin America intensive care network (LIVEN). Effect of a resuscitation strategy targeting peripheral perfusion status vs Serum lactate levels on 28-day mortality among patients with septic shock: the ANDROMEDA-SHOCK randomized clinical trial. *JAMA* 2019;321(7):654–664. DOI: 10.1001/jama.2019.0071.
7. Weiss SL, Fitzgerald JC, Balamuth F, Alpern ER, Lavelle J, Chilutti M, et al. Delayed antimicrobial therapy increases mortality and organ dysfunction duration in pediatric sepsis. *Crit Care Med* 2014;42(11):2409–2417. DOI: 10.1097/CCM.0000000000000509.
8. Moisey LL, Mourtzakis M, Cotton BA, Premji T, Heyland DK, Wade CE, et al. Skeletal muscle predicts ventilator-free days, ICU-free days, and mortality in elderly ICU patients. *Crit Care* 2013;17(5):R206. DOI: 10.1186/cc12901.
9. Fu Y, Chong SL, Lee JH, Liu C, Fu S, Loh TF, et al. The impact of early hyperglycaemia on children with traumatic brain injury. *Brain Inj* 2017;31(3):396–400. DOI: 10.1080/02699052.2016.1264629.
10. Agus MS, Wypij D, Hirshberg EL, Srinivasan V, Faustino EV, Luckett PM, et al. HALF-PINT study investigators and the PALISI network. Tight glycemic control in critically ill children. *N Engl J Med* 2017;376(8):729–741. DOI: 10.1056/NEJMoa1612348.
11. Kelmenson DA, Held N, Allen RR, Quan D, Burnham EL, Clark BJ, et al. Outcomes of ICU patients with a discharge diagnosis of critical illness polyneuromyopathy: a propensity-matched analysis. *Crit Care Med* 2017;45(12):2055–2060. DOI: 10.1097/CCM.0000000000002763.
12. Yoshikawa H, Iwata M, Matsuzaki H, Ono R, Murakami Y, Taba N, et al. Impact of omalizumab on medical cost of childhood asthma in Japan. *Pediatr Int* 2016;58(5):425–428. DOI: 10.1111/ped.12936.
13. Delano MJ, Ward PA. Sepsis-induced immune dysfunction: can immune therapies reduce mortality? *J Clin Invest* 2016;126(1):23–31. DOI: 10.1172/JCI82224.
14. Watson RS, Carcillo JA. Scope and epidemiology of pediatric sepsis. *Pediatr Crit Care Med* 2005;6(3 Suppl):S3–S5. DOI: 10.1097/01.PCC.0000161289.22464.C3.
15. Carcillo JA, Sward K, Halstead ES, Telford R, Jimenez-Bacardi A, Shakoory B, et al. Eunice kennedy shriver national institute of child health and human development collaborative pediatric critical care research network Investigators. A systemic inflammation mortality risk assessment contingency table for severe sepsis. *Pediatr Crit Care Med* 2017;18(2):143–150. DOI: 10.1097/PCC.0000000000001029.
16. Carcillo JA, Halstead ES, Hall MW, Nguyen TC, Reeder R, Aneja R, et al. Eunice kennedy shriver national institute of child health and human development collaborative pediatric critical care research network investigators. Three hypothetical inflammation pathobiology phenotypes and pediatric sepsis-induced multiple organ failure outcome. *Pediatr Crit Care Med* 2017;18(6):513–523. DOI: 10.1097/PCC.0000000000001122.
17. Spicer AC, Calfee CS, Zinter MS, Khemani RG, Lo VP, Alkhouli MF, et al. A simple and robust bedside model for mortality risk in pediatric patients with acute respiratory distress syndrome. *Pediatr Crit Care Med* 2016;17(10):907–916. DOI: 10.1097/PCC.0000000000000865.
18. Papazian L, Forel JM, Gacouin A, Penot-Ragon C, Perrin G, Loundou A, et al. ACURASYS study investigators. Neuromuscular blockers in early acute respiratory distress syndrome. *N Engl J Med* 2010;363(12):1107–1116. DOI: 10.1056/NEJMoa1005372.
19. Baranwal AK, Murthy AS, Singhi SC. High-dose oral ambroxol for early treatment of pulmonary acute respiratory distress syndrome: an exploratory, randomized, controlled pilot trial. *J Trop Pediatr* 2015;61(5):339–350. DOI: 10.1093/tropej/fmv033.

20. Ghosh S, Baranwal AK, Bhatia P, Nallasamy K. Suspecting hyperferritinemic sepsis in iron-deficient population: do we need a lower plasma ferritin threshold? *Pediatr Crit Care Med* 2018;19(7):e367–e373. DOI: 10.1097/PCC.0000000000001584.
21. Tan B, Wong JJ, Sultana R, Koh JCJW, Jit M, Mok YH, et al. Global case-fatality rates in pediatric severe sepsis and septic shock: a systematic review and meta-analysis. *JAMA Pediatr* 2019;173(4):352–362. DOI: 10.1001/jamapediatrics.2018.4839.
22. Haque A, Siddiqui NR, Munir O, Saleem S, Mian A. Association between vasoactive-inotropic score and mortality in pediatric septic shock. *Indian Pediatr* 2015;52(4):311–313. DOI: 10.1007/s13312-015-0630-1.
23. Khan MR, Maheshwari PK, Masood K, Qamar FN, Haque AU. Epidemiology and outcome of sepsis in a tertiary care PICU of Pakistan. *Indian J Pediatr* 2012;79(11):1454–1458. DOI: 10.1007/s12098-012-0706-z.
24. Kaur G, Vinayak N, Mittal K, Kaushik JS, Aamir M. Clinical outcome and predictors of mortality in children with sepsis, severe sepsis, and septic shock from Rohtak, Haryana: a prospective observational study. *Indian J Crit Care Med* 2014;18(7):437–441. DOI: 10.4103/0972-5229.136072.
25. Barreira ER, Munoz GO, Cavalheiro PO, Suzuki AS, Degaspere NV, Shieh HH, et al. Epidemiology and outcomes of acute respiratory distress syndrome in children according to the Berlin definition: a multicenter prospective study. *Crit Care Med* 2015;43(5):947–953. DOI: 10.1097/CCM.0000000000000866.
26. Gupta S, Sankar J, Lodha R, Kabra SK. Comparison of prevalence and outcomes of pediatric acute respiratory distress syndrome using pediatric acute lung injury consensus conference criteria and Berlin definition. *Front Pediatr* 2018;6:93. DOI: 10.3389/fped.2018.00093.
27. Lalgudi Ganesan S, Jayashree M, Chandra Singhi S, Bansal A. Airway pressure release ventilation in pediatric acute respiratory distress syndrome. A randomized controlled trial. *Am J Respir Crit Care Med* 2018;198(9):1199–1207. DOI: 10.1164/rccm.201705-0989OC.
28. Wong JJ, Loh TF, Testoni D, Yeo JG, Mok YH, Lee JH. Epidemiology of pediatric acute respiratory distress syndrome in Singapore: risk factors and predictive respiratory indices for mortality. *Front Pediatr* 2014;2:78. DOI: 10.3389/fped.2014.00078.
29. Kumar R, Singhi S, Singhi P, Jayashree M, Bansal A, Bhatti A. Randomized controlled trial comparing cerebral perfusion pressure-targeted therapy versus intracranial pressure-targeted therapy for raised intracranial pressure due to acute CNS infections in children. *Crit Care Med* 2014;42(8):1775–1787. DOI: 10.1097/CCM.0000000000000298.
30. Panico FF, Troster EJ, Oliveira CS, Faria A, Lucena M, João PRD, et al. Risk factors for mortality and outcomes in pediatric acute lung injury/acute respiratory distress syndrome. *Pediatr Crit Care Med* 2015;16(7):e194–e200. DOI: 10.1097/PCC.0000000000000490.
31. Rudd KE, Kisson N, Limmathurotsakul D, Bory S, Mutahunga B, Seymour CW, et al. The global burden of sepsis: barriers and potential solutions. *Crit Care* 2018;22(1):232. DOI: 10.1186/s13054-018-2157-z.
32. Yehya N, Harhay MO, Curley MAQ, Schoenfeld DA, Reeder RW. Reappraisal of ventilator-free days in critical care research. *Am J Respir Crit Care Med* 2019;200(7):828–836. DOI: 10.1164/rccm.201810-2050CP.
33. Aparna S. Efficacy of high dose oral ambroxol therapy in children ventilated for Acute Lung Injury: a randomized placebo-controlled double-blind pilot study. MD (Pediatrics) dissertation submitted to Postgraduate Institute of Medical Education & Research, Chandigarh, India. December, 2008.
34. Choudhary A. A pilot randomized controlled trial comparing lower versus higher hemoglobin threshold for transfusion in children with acute respiratory distress syndrome. DM (Pediatric Critical Care) dissertation submitted to Postgraduate Institute of Medical Education & Research, Chandigarh, India. December, 2016.
35. Gupta S. A randomized controlled trial of normal saline versus plasmalyte as resuscitation fluid in children with septic shock. DM (Pediatric Critical Care) dissertation submitted to Postgraduate Institute of Medical Education & Research, Chandigarh, India. December, 2016.
36. Yadav B, Bansal A, Jayashree M. Clinical profile and predictors of outcome of pediatric acute respiratory distress syndrome in a PICU: a prospective observational study. *Pediatr Crit Care Med* 2019;20(6):e263–e273. DOI: 10.1097/PCC.0000000000001924.
37. Jain P. Comparative study on the outcome of early goal-directed therapy (EGDT) versus standard care in pediatric septic shock patients: A prospective open labelled randomized controlled trial. DM (Pediatric Critical Care) dissertation submitted to Jawaharlal Institute of Postgraduate Medical Education & Research, Puducherry, India. December, 2017.
38. Core Team R. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. (2018). Available at: <https://www.R-project.org/> Accessed Jan 1, 2019.
39. Champely S. pwr: Basic Functions for Power Analysis. 2018; Available at: <https://CRAN.R-project.org/package=pwr> Accessed Jan 1, 2019.
40. Wickham H. ggplot2: Elegant Graphics for Data Analysis. 2016; Available at: <http://ggplot2.org>. Accessed Jan 1, 2019.
41. Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez JC, et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. *BMC Bioinformatics* 2011;12(1):77. DOI: 10.1186/1471-2105-12-77.
42. Moss M, Huang DT, Brower RG, Ferguson ND, Ginde AA, Gong MN, et al. Early neuromuscular blockade in the acute respiratory distress syndrome. *N Engl J Med* 2019;380(21):1997–2008. DOI: 10.1056/NEJMoa1901686.
43. Hirshberg EL, Lanspa MJ, Peterson J, Carpenter L, Wilson EL, Brown SM, et al. Randomized feasibility trial of a low tidal volume-airway pressure release ventilation protocol compared with traditional airway pressure release ventilation and volume control ventilation protocols. *Crit Care Med* 2018;46(12):1943–1952. DOI: 10.1097/CCM.00000000000003437.
44. Villar J, Ferrando C, Martínez D, Ambrós A, Muñoz T, Soler JA, et al. For dexamethasone in ARDS network. dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. *Lancet Respir Med* 2020;8(3):267–276. DOI: 10.1016/S2213-2600(19)30417-5.
45. Novack V, Beitler JR, Yitshak-Sade M, Thompson BT, Schoenfeld DA, Rubenfeld G, et al. Alive and ventilator free: A hierarchical, composite outcome for clinical trials in the acute respiratory distress syndrome. *Crit Care Med* 2020;48(2):158–166. DOI: 10.1097/CCM.0000000000004104.